Regulatory

Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm

2021-04-15
PDF

The board of directors of Ascelia Pharma AB (”Ascelia Pharma” or the “Company”) has, as a result of the directed issue of 5,000,000 shares to a number of Swedish and international institutional investors, that was published on 17 March 2021 and approved by the extraordinary general meeting on 13 April 2021, prepared a prospectus for admission to trading of the new shares on Nasdaq Stockholm. The prospectus does not constitute an offering to subscribe for shares or otherwise acquire shares in Ascelia Pharma. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) and is now available on Ascelia Pharma’s website, www.ascelia.com, and will be made available on the Swedish Financial Supervisory Authority’s website, www.fi.se.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (THE “UNITED STATES”), AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.